Ethmoid Sinus Adenocarcinoma — Comprehensive Research Report

Prepared: 2026-08-28 · Target concept: Ethmoid sinus adenocarcinoma (MONDO:0002418) · Category: Head and neck cancer / rare cancer / occupational cancer

Scope note, read first

The literature is almost entirely sinonasal-level, not ethmoid-subsite-level. Nearly every molecular, occupational, and outcome study cited below is reported for sinonasal adenocarcinoma or, more narrowly, sinonasal intestinal-type adenocarcinoma (ITAC) pooled across sinus subsites. The ethmoid is the subsite ITAC most characteristically occupies — roughly 40% of ITAC by subsite in one recent review, and ~85% when the ethmoid and adjacent upper nasal cavity are counted together — which is why MONDO:0002418 is a workable anchor. But there is no MONDO class for sinonasal ITAC, and the mapping is imperfect: some ethmoid adenocarcinomas are non-ITAC, and some ITACs arise in the maxillary sinus or nasal cavity. Where a claim below is sinonasal-level rather than ethmoid-specific, it is marked. A future MONDO ITAC class would be the better anchor for most of this content.

1. Disease Information

Overview

Adenocarcinoma of the ethmoid sinus is the glandular (non-squamous, non-salivary) malignancy of the sinonasal tract, and the ethmoid labyrinth is the sinus subsite it most characteristically occupies. Two biologically distinct entities sit under the heading:

• Intestinal-type adenocarcinoma (ITAC) — a tumour that reproduces the morphology and immunophenotype of colorectal epithelium (CDX2, CK20, MUC2, SATB2, villin) in a sinus containing no intestinal tissue of origin. This is the classic occupational cancer of the head and neck.
• Non-intestinal-type adenocarcinoma (non-ITAC) — a rarer, non-salivary, non-enteric group split into low-grade and high-grade forms; the low-grade form is increasingly understood as seromucinous-gland-derived (PMID:35322195).

ITAC's defining clinical behaviour is local aggression without much metastatic drive: "These tumors are locally aggressive with frequent local recurrences in up to 50% of cases. Metastasis to regional lymph nodes and distant metastasis are less frequent (10%). Invasion of the duramater and local recurrence are frequent and the major cause of death" (Llorente et al., Eur Arch Otorhinolaryngol 2009; PMID:18560862).

Identifiers

Synonyms

Sinonasal intestinal-type adenocarcinoma; ITAC; adenocarcinoma of the ethmoid sinus; ethmoidal adenocarcinoma; "woodworker's nasal cancer" (historical/colloquial); papillary-tubular cylinder cell adenocarcinoma of the inner nose (Kleinsasser terminology).

Data provenance

All content below is derived from aggregated disease-level resources — published case series, registry analyses (SEER), systematic reviews, and molecular cohort studies. No individual-patient EHR-derived content is used.

2. Etiology

2.1 Primary causal factor: occupational hardwood and leather dust

This is the strongest exposure–histology association in head and neck oncology, and it is specific to the adenocarcinoma histology rather than to sinonasal cancer generally.

Binazzi et al., BMC Cancer 2015 (PMID:25885319) — 28 studies (11 cohort, 17 case-control) meta-analysed:

"Exposure to wood dust results associated with SNC (RRpooled = 5.91, 95% CI: 4.31-8.11 for the case-control studies and 1.61, 95% CI: 1.10-2.37 for the cohort studies), as well as to leather dust (11.89, 95% CI: 7.69-18.36). The strongest associations are with adenocarcinomas (29.43, 95% CI: 16.46-52.61 and 35.26, 95% CI: 20.62-60.28 respectively)."

The same paper reports an exposure–response relationship for wood dust (p = 0.001) — a Bradford Hill criterion that matters for causal inference.

Note the magnitude comparison this enables: pooled RR ≈ 29 (wood) and ≈ 35 (leather) for adenocarcinoma, versus RR ≈ 5.9 / 11.9 for sinonasal cancer of all histologies. The adenocarcinoma-specific effect is roughly an order of magnitude above the all-histology effect.

Other occupational exposures from the same meta-analysis (sinonasal cancer, all histologies): nickel and chromium compounds RR 18.0 (95% CI 14.55–22.27); textile industry RR 2.03 (1.47–2.80); formaldehyde RR 1.68 (1.37–2.06, case-control) and 1.09 (0.66–1.79, cohort); construction RR 1.62 (1.11–2.36).

Formaldehyde is a specific caution. It is a confounder of wood-dust exposure (co-exposure in woodworking is near-universal), and its independent contribution to adenocarcinoma is weak. Holmila et al. found that "adjustment for formaldehyde affected the ORs only slightly" (PMID:19950227). A 2025 review states that established carcinogens including formaldehyde and asbestos have not been confirmed for adenocarcinoma development specifically (Sciacca et al., Medicina 2025; PMID:41303732).

IARC classification. Wood dust is IARC Group 1 (carcinogenic to humans), with the 1995 Monograph (Vol. 62) finding a clear association specifically between adenocarcinoma of the nasal cavity/paranasal sinuses and hardwood dust. Latency is very long — mean ~40 years from first exposure (range 7–70 years), which is the single most operationally important etiologic fact for both compensation and surveillance.

Attributable fraction. A 2025 review reports "88% of ITAC cases attributed to occupational exposure," with wood dust the primary factor followed by textile products; the remaining ~12% are sporadic, occur disproportionately in women, and carry a worse prognosis (PMID:41303732). Odds ratio for the wood-dust→adenocarcinoma-histology association specifically: OR 12.6 (95% CI 5.0–31.6) (PMID:19950227).

Other reported exposures. Cork dust has been proposed as an additional risk exposure in a retrospective cohort (PMC7531325); the evidence base is much thinner than for wood/leather.

2.2 Genetic risk factors

There is no established Mendelian or common-variant susceptibility for this tumour. It is not a hereditary cancer syndrome, and no GWAS has been performed at usable scale (the disease is far too rare).

One finding deserves flagging as new and unreplicated: Riobello et al. sequenced 50 ITACs with 29 matched germline samples and reported "the first report on hereditary germline mutations in ITAC" — 11 germline mutations in 8 of 29 matched cases, concentrated in DNA-damage-response genes (ATM, BRCA1, BRCA2) (Cancers 2021; PMID:34638506). The companion paper makes the methodological point that this cuts both ways: "Matched tumor/germline comparison in 27 cases revealed that 57% were in fact germline variants" — i.e. tumour-only sequencing of ITAC massively over-calls somatic drivers (PMID:33500480). Whether these germline DDR variants represent genuine predisposition or incidental population variation is unresolved.

2.3 Environmental / demographic risk factors

• Occupation (dominant): woodworking, furniture and cabinet making, sawmilling, joinery, carpentry; leather tanning and shoemaking; textile work.
• Sex: overwhelmingly male — 94.7% male in a 1,126-case ethmoid/sphenoid ITAC meta-analysis (PMID:34622832). This is almost certainly occupational-cohort composition rather than a biological sex effect; note that sporadic (non-occupational) ITAC is enriched in women.
• Age: mean 64.7 years in the ethmoid/sphenoid meta-analysis; ITAC predominantly affects males aged 50–64 (PMID:41303732). A Pakistani series reported a notably younger mean of 44 years (range 22–79), suggesting geographic/occupational-pattern variation (PMID:39924774).
• Tobacco smoking: not an established risk factor for ITAC. Holmila et al.: "Smoking did not influence the occurrence of TP53 mutation; however, it was associated with multiple mutations (p = 0.03)." The mutational-signature work confirms tobacco signatures appear only in smokers and are not the ITAC-defining signal (PMID:38711096).

2.4 Protective factors

No genetic protective variants are known. Environmental protection is entirely engineering/administrative: dust extraction at source, respiratory protection, and enforced occupational exposure limits. Under EU Directive 2017/2398 (amending the Carcinogens and Mutagens Directive), the binding OEL for inhalable hardwood dust was set at 3 mg/m³ for a transitional five years and then lowered to 2 mg/m³ (effective 17 January 2023; Germany adopted 2 mg/m³ in March 2021). This threshold is directly informed by the dose–response data: Holmila et al. found TP53-mutation risk significantly elevated at average exposure >2 mg/m³ (OR 3.6, 95% CI 1.2–10.8) and cumulative exposure ≥30 mg/m³·years (OR 3.5, 1.2–10.7).

2.5 Gene–environment interaction

The best-characterised gene–environment interaction in this disease is wood dust × TP53, and it is a dose-dependent one:

"Risk of TP53 mutation was significantly increased in association with duration (≥24 years, OR 5.1, 95% CI, 1.5-17.1), average level (>2 mg/m³; OR 3.6, 95% CI, 1.2-10.8) and cumulative level (≥30 mg/m³ × years; OR 3.5, 95% CI, 1.2-10.7) of wood-dust exposure" (PMID:19950227).

Whole-genome sequencing gives the mechanistic complement: "Mutation burden was higher in samples of wood dust-exposed patients (p = 0.016). Reactive oxygen species (ROS) damage-related mutational signatures were almost exclusively identified in ITAC subtype samples (p = 0.00055)" (Sipilä et al., Genes Environ 2024; PMID:38711096). The signatures involved are COSMIC SBS18/SBS36 — oxidative-damage signatures, not direct-adduct signatures. This is the molecular evidence for the "inflammation-mediated, not directly genotoxic" model of wood-dust carcinogenesis.

3. Phenotypes

3.1 Presenting clinical features

Symptoms are unilateral, non-specific, and easily mistaken for chronic rhinosinusitis, which is the principal driver of late-stage presentation. Barnes' original 17-case series recorded "Unilateral nasal obstruction and epistaxis, averaging 6.8 months in duration, were the most common symptoms" (PMID:3953940).

A 48-patient series confirms the pattern: "Most patients were presented with nasal blockage and difficulty in breathing" (PMID:39924774).

3.2 Phenotype characteristics

• Age of onset: adult, typically 6th–7th decade (mean 64.7 y in the ethmoid/sphenoid meta-analysis). Effectively determined by the ~40-year exposure latency. Never congenital or paediatric.
• Onset pattern: insidious. Median symptom duration before diagnosis ~6.8 months (PMID:3953940).
• Severity: variable at presentation, but stage is advanced in most cases — Franchi et al. found "92.6% of patients had T3 or T4 carcinomas" (PMID:10534159).
• Progression: progressive, locally destructive, without spontaneous remission.
• Laterality: characteristically unilateral at presentation; bilateral extension occurs late via the perpendicular plate/septum.

3.3 Quality-of-life impact

No ITAC-specific EQ-5D / SF-36 / PROMIS data were identified in this search — this is a genuine gap. Qualitatively, the QoL burden is driven by (a) permanent anosmia/hyposmia after resection of the olfactory cleft, (b) orbital exenteration when the orbit is invaded, (c) chronic crusting and nasal dryness after extensive endoscopic resection, and (d) xerostomia/visual toxicity from adjuvant radiotherapy to a field abutting the optic apparatus. Flag as a knowledge gap.

4. Genetic / Molecular Information

4.1 The headline result: no characterising driver

This is the most important single molecular statement about ITAC, and it is unusual for a carcinoma with such a stereotyped morphology:

"The wide spectrum of gene mutations suggests that ITAC is a genetically heterogeneous without specific characterizing gene mutations" — Riobello et al., Cancers 2021 (PMID:34638506).

The same group found "72% of tumors affected by gene defects in Wnt, DNA-damage response, MAPK and/or PI3K pathways" — but "not in a mutually exclusive manner," and "None of the alterations were related to histological ITAC subtype, tumor stage or survival" (PMID:33500480).

4.2 TP53 — the one recurrent, exposure-linked alteration

TP53 (hgnc:11998) is the closest thing ITAC has to a defining gene, and it is the gene through which the occupational exposure acts.

• Frequency, sinonasal cancer overall: 77% (all histologies, n=358), with adenocarcinoma the histology most likely to be mutation-positive (OR 2.0, 95% CI 1.1–3.7 vs. SCC) (PMID:19950227).
• Frequency, ITAC specifically: highly variable across series — 18% in an early small genotyping study (2/11; PMID:8685214), 40–50% in most modern series, 50% (4/8) in the WGS cohort (PMID:38711096); reviews quote a range of 18–86%. The variability is largely assay-driven (IHC vs. exon 5–8 sequencing vs. full-gene sequencing).
• Mutation spectrum tracks wood dust, not tobacco: G→A transitions predominate (~50%, 9/18) and occur almost exclusively in nonsmokers, while G→T transversions (~27%, 5/18) are found only in smokers.
• Historical caution: Wu et al. 1996 reported "58% of ITAC demonstrated scattered positive p53 immunohistochemical nuclear staining, but no mutations were identified in exon-5 through exon-8 by genotyping" (PMID:8685214) — p53 IHC is not a reliable surrogate for TP53 mutation in this tumour.

4.3 Pathway-level mutation landscape (Riobello et al., 50 ITACs, 120-gene panel; PMID:34638506)

Note the striking disconnect between mutation and pathway activity: p-mTOR is positive in 88% of tumours but PI3K-pathway mutations occur in only ~22%, and p-ERK1/2 in 76% versus 22% MAPK mutations. "Expression of key pathway proteins showed no correlation to mutations in these pathways, except for nuclear β-catenin and APC/CTNNB1 mutation." Pathway activation in ITAC is therefore mostly not explained by mutation — a genuinely open mechanistic question.

4.4 KRAS — a discordant literature worth stating explicitly

Reported KRAS frequencies span 0% → 12–16% → 43–50% across series. Wu et al. 1996: "In contrast to colorectal adenocarcinoma, which demonstrates K-ras-2 mutation in about 50% of cases, ITAC showed no evidence of K-ras-2 mutation" (PMID:8685214). Modern panel sequencing gives 12% (PMID:34638506). The high figures come from small older series. Any KB entry should record the range, not a point estimate.

4.5 HER2/ERBB2 — a negative result that closed a therapeutic hypothesis

Maffeis et al. tested 43 ITACs by IHC and CISH: "83.7% (36/43) of ITAC were scored 0, 14% (6/43) 1+, and 2.3% (1/43) 2+. No HER2 amplification was detected by CISH … our findings seem to rule out any oncogenetic role of HER2 in ITAC pathogenesis" (PMID:31047725). This supersedes earlier positive c-erbB-2 IHC reports (e.g. PMID:9570628).

4.6 Chromosomal abnormalities / copy number

ITAC is chromosomally unstable, with a recurrent pattern. Korinth et al. applied CGH to 42 wood-dust-related sinonasal adenocarcinomas: "Copy number changes were detected in 41 tumours (97.6%)."

• Gains: 12p (83%), 7q (74%), 8q (71%), 20q (71%), 11q (61%), 22 (59%), 1q (52%); high-level amplification most often at 8q (36%).
• Losses: 5q (81%), 18q (76%), chromosome 4 (74%), 8p (61%), 9p (60%), 6q and 17p (52% each), 3p/13q/21 (50% each).
• Grade correlation: "a quantitative as well as a qualitative increase of alterations from PTCC-G1 to PTCC-G2 and finally PTCC-G3 … PTCC-G3 showed significantly more gains of 7q, 8q, and 12p, and losses of 8p and 17p" (PMID:16041693). Note the 5q and 18q losses and 8q/20q gains mirror the colorectal pattern — the morphologic mimicry extends to the karyotype.

WGS adds recurrent gains in COSMIC Cancer Gene Census genes TERT, SDHA, RAC1, ETV1, PCM1, and MYC, plus a tetraploidy copy-number signature enriched in ITAC (p = 0.042) (PMID:38711096).

4.7 Mismatch repair / microsatellite instability

ITAC appears to be MMR-proficient, unlike a subset of colorectal cancer. Puccio et al. examined 32 ITACs: "no alterations regarding MMR proteins were identified" (PMID:38791973). This is a clinically consequential negative — it argues against MSI-high as a route to checkpoint-inhibitor eligibility in ITAC.

4.8 Non-ITAC molecular landscape — completely different

Low-grade non-intestinal-type SNAC is defined by kinase fusions and hotspot mutations, not by TP53/CIN. Rooper et al., 18 cases (PMID:35322195):

"likely oncogenic molecular alterations were identified in 76% of cases, most notably including CTNNB1 p.S33F mutations in 2 cases, concomitant BRAF p.V600E and AKT1 p.E17K mutations in 2 cases, and ETV6::NTRK3, PRKAR1A::MET, FN1::NRG1, and DNAJB1::PRKACA fusions in 1 case each."

Genotype–phenotype correlations exist: CTNNB1-mutant cases showed intermixed squamoid morules; BRAF/AKT1 cases showed a myoepithelial population and papillary/micropapillary architecture. ETV6::NTRK3 is directly actionable (larotrectinib/entrectinib) — the single most important reason to genotype a low-grade non-ITAC.

4.9 Epigenetics

Not systematically characterised. No comprehensive methylation-profiling study of ITAC was identified in this search. Flag as a knowledge gap.

4.10 Gene symbols for annotation

TP53 (hgnc:11998), APC (hgnc:583), CTNNB1 (hgnc:2514), KRAS (hgnc:6407), PIK3CA (hgnc:8975), ATM (hgnc:795), BRCA1 (hgnc:1100), BRAF (hgnc:1097), NF1 (hgnc:7765), CDX2 (hgnc:1806), MUC2 (hgnc:7512), ERBB2 (hgnc:3430), ETV6 (hgnc:3495), NTRK3 (hgnc:8033), MYC (hgnc:7553), TERT (hgnc:11730). (HGNC numeric IDs should be re-verified against the HGNC cache before use; the symbols are the reliable part.)

5. Environmental Information

Covered in §2. Summary for annotation:

Infectious agents: none. Unlike sinonasal squamous cell carcinoma (HPV-associated in a subset) and nasopharyngeal carcinoma (EBV), no viral etiology is established for ITAC. No HPV-prevalence study in ITAC surfaced in this search.

Note the absent ECTO term. There is no exposure to leather dust class in ECTO — this is a real ontology gap for the second-strongest exposure in the disease, and worth a term request rather than a forced binding to generic dust exposure.

6. Mechanism / Pathophysiology

6.1 The causal chain, upstream → downstream

Step 1 — Deposition (ORGANISM scale). Inhaled hardwood/leather dust particles impact on the anterior ethmoid and middle turbinate. This is airflow physics, and it is why the ethmoid is the characteristic site: the region is the principal impaction zone for inhaled particulate in the nasal airway. Exposure node: ECTO:7000135. Anatomy: UBERON:0002453 ethmoid sinus, UBERON:0005385 nasal cavity respiratory epithelium.

Step 2 — Impaired mucociliary clearance and prolonged residence time (TISSUE). Dust burden slows clearance, extending contact time between particulate and epithelium.

Step 3 — Chronic inflammation and oxidative/nitrosative stress (TISSUE/MOLECULAR). The critical mechanistic claim, and the one that distinguishes this from a classic adduct-forming carcinogen: wood dust is not thought to be directly mutagenic. Prolonged irritation drives inflammatory cell turnover, and the resulting reactive oxygen/nitrogen species do the mutagenesis. The WGS evidence is the strongest support: ROS-damage signatures (SBS18/SBS36) were "almost exclusively identified in ITAC subtype samples (p = 0.00055)" and mutation burden was elevated in exposed patients (p = 0.016) (PMID:38711096). GO: GO:0002544 chronic inflammatory response, GO:0006954 inflammatory response, GO:0006979 response to oxidative stress. CHEBI: CHEBI:26523 reactive oxygen species, CHEBI:62764 reactive nitrogen species.

Step 4 — Reactive epithelial change: goblet cell hyperplasia (CELLULAR). Palomba et al. biopsied middle-turbinate mucosa in 139 leatherworkers (10–48 years employed, median 29): squamous metaplasia in 64.7%, with mild-moderate dysplasia in 41.1%, and goblet cell hyperplasia in 21.6%. "Positivity for MUC-2 was detected in goblet cells of 20 of the 30 samples with goblet cell hyperplasia (66.6%), whereas no immunostaining was observed for cytokeratin 20 and CDX-2. Presence of goblet cell hyperplasia was significantly associated with longer occupational exposure … (p = 0.03)" (PMID:18702897). The MUC2-positive/CDX2-negative profile places this before full intestinal commitment. CL: CL:0000160 goblet cell, CL:0002370 respiratory tract goblet cell.

Step 5 — Intestinal metaplasia: the putative precursor lesion (TISSUE). Franchi et al. examined mucosa adjacent to 29 ITACs: foci of intestinal metaplasia in 8 cases (27.5%), "all positive for CK20 and CDX2, while MUC2 was detected in six cases (75%)"; 75% showed dysplasia. Decisively, "TP53 gene sequencing … revealed the same mutation in both IM and ITAC in two cases (c.832C > T and c.215G > C)," supporting "a possible clonal relationship between areas of sinonasal IM and ITAC, indicating that IM may represent a precursor lesion of ITAC" (PMID:25431194). One case showed a mutation in the ITAC absent from the adjacent IM — i.e. the relationship is clonal but the lesions are not identical, consistent with IM as an early field with subsequent divergent progression.

Step 6 — TP53 mutation (MOLECULAR). Dose-dependent on cumulative wood-dust exposure (§2.5). G→A transition spectrum in nonsmokers. GO: GO:0072331 signal transduction by p53 class mediator (modifier: LOSS_OF_FUNCTION); GO:0006974 cellular response to DNA damage stimulus.

Step 7 — Chromosomal instability and aneuploidy (MOLECULAR/CELLULAR). 97.6% of tumours carry copy-number change; alteration load increases monotonically with histologic grade G1→G2→G3 (PMID:16041693). Tetraploidy signature enrichment in ITAC (PMID:38711096).

Step 8 — Heterogeneous pathway activation (CELLULAR). Wnt (nuclear β-catenin 52%), MAPK (p-ERK1/2 76%), PI3K-mTOR (p-mTOR 88%), DDR defects (32%), RTK gains (44%) — largely non-mutually-exclusive and largely uncorrelated with mutation status except for Wnt. GO: GO:0016055 Wnt signaling pathway, GO:0000165 MAPK cascade, GO:0008283 cell population proliferation.

Step 9 — Local invasion (TISSUE/ORGANISM), the lethal step. Extension through the lamina papyracea into the orbit (UBERON:0001697 orbit of skull) and through the cribriform plate (UBERON:0004546 cribriform plate) into the anterior cranial fossa and dura (UBERON:0002363 dura mater). "Invasion of the duramater and local recurrence are frequent and the major cause of death" (PMID:18560862).

Step 10 — Tumour budding at the invasive front (CELLULAR). Puccio et al. established this as an independent prognostic mechanism, borrowed from colorectal pathology: "Patients with high TB (>4) have an increased risk of recurrence and death compared to those with low TB, with a median survival of 13 and 54 months, respectively. On multivariate analysis … TB emerged as an independent prognostic factor net of the stage of disease or type of therapy received" (PMID:38791973).

6.2 Immune microenvironment

ITAC is poorly immunogenic, which sets the ceiling on checkpoint-inhibitor expectations. García-Marín et al., 133 ITACs: "The presence of intratumoural CD8+ TILs was low in 57% of cases and high in 8% of cases. Tumoural PD-L1 positivity was observed in 26% of cases … The modest percentage of CD8high/PD-L1pos cases indicates that ITAC is a lowly immunogenic tumour type. Nevertheless, a proportion of ITAC, especially the papillary and colonic subtypes, could benefit from therapy with immune checkpoint inhibitors" (PMID:32353928). Comparative figures: PD-L1 >5% tumour cells in 34% of sinonasal SCC vs 17% of ITAC; >50% in 26% of SCC vs 3% of ITAC (PMID:41303732; original data PMID:29356178). GO: GO:0002456 T cell mediated immunity. CL: CL:0000625 CD8-positive, alpha-beta T cell.

6.3 Molecular profiling status

The genomics/everything-else asymmetry is stark and is the clearest research gap in the disease.

7. Anatomical Structures Affected

Primary site. Ethmoid labyrinth (UBERON:0002453 ethmoid sinus) and adjacent superior/middle nasal cavity (UBERON:0001707 nasal cavity). Subsite distribution for ITAC in one recent review: ethmoid sinus 40%, nasal cavity 25%, maxillary antrum 20% (PMID:41303732); pooling ethmoid + upper nasal cavity gives ~85%. Contrast with sporadic ITAC in Barnes' original series, where the maxillary sinus predominated (8/17 maxillary, 7/17 nasal cavity, 2/17 ethmoid) — "In contrast, ITAC in woodworkers occurs primarily in men, originates almost exclusively in the nasal cavity or ethmoid sinus, and has a better prognosis" (PMID:3953940). Subsite is therefore an etiologic marker, not just a location.

Secondary involvement by contiguity. Orbit via lamina papyracea (UBERON:0001697); anterior skull base via cribriform plate (UBERON:0004546); dura and frontal lobe (UBERON:0002363 dura mater); sphenoid sinus; nasolacrimal apparatus; pterygopalatine fossa. Systems: respiratory (upper), nervous (via skull base), visual/orbital.

Tissue level. Sinonasal respiratory (pseudostratified ciliated columnar) epithelium (UBERON:0005385) and its seromucinous submucosal glands — the latter being the presumed origin of low-grade non-ITAC.

Cell types. CL:0000066 epithelial cell (the malignant compartment); CL:0000160 goblet cell / CL:0002370 respiratory tract goblet cell (hyperplasia and metaplasia precursor); CL:0000151 secretory cell (seromucinous glands, non-ITAC origin); CL:0000625 CD8+ T cell and macrophages (microenvironment).

Subcellular. Nucleus (GO:0005634) — nuclear β-catenin accumulation, p53 accumulation, CDX2/SATB2 nuclear staining are all read out here. No mitochondrial, lysosomal, or ER compartment mechanism is established.

Laterality. Characteristically unilateral at presentation; a unilateral sinonasal mass in a woodworker is the classic clinical trigger for biopsy.

8. Temporal Development

• Onset: adult/geriatric; mean 64.7 y (ethmoid/sphenoid ITAC meta-analysis, PMID:34622832); median 64 y for sinonasal adenocarcinoma in SEER; SEER SNAC incidence peaks in 60–69-year-olds (PMID:39753118).
• Latency: ~40 years mean from first wood-dust exposure (range 7–70), per IARC. This is the defining temporal fact — it means incidence today reflects exposure conditions of the 1970s–80s, and that OEL improvements will not show up in incidence data for decades.
• Onset pattern: insidious; median ~6.8 months of symptoms before diagnosis (PMID:3953940).
• Staging: AJCC 8th edition, with the nasal-cavity/ethmoid-sinus scheme (distinct from the maxillary-sinus scheme). Most patients present T3–T4 (92.6% in Franchi's series, PMID:10534159).
• Course: progressive, locally destructive. Recurrence is the dominant event, not metastasis:
• Local recurrence 32.2% (244/757), regional 2.2% (22/1,022), distant 10.3% (89/861) (PMID:34622832).
• Barnes' 213-case pooled historical figure was harsher: 53% local recurrence, 8% nodal, 13% distant, 60% dead of disease, "Of those dying, 80% did so within 3 years of diagnosis" (PMID:3953940).
• Nodal metastasis <10% at presentation; distant metastasis (lung, bone) <5% at diagnosis (PMID:41303732).
• Late recurrence is real. Recurrences beyond five years are documented, and lifelong follow-up is recommended (PMID:41303732).
• Remission: treatment-induced only. Pathological complete remission after induction chemotherapy is achievable and durable in the right molecular subgroup (§12.3). No spontaneous remission.
• Critical intervention window: the interval between symptom onset and skull-base/dural breach. Once dura is invaded, R0 resection becomes difficult and this is the principal determinant of death.

9. Inheritance and Population

Epidemiology

Trend data conflict and should be reported as such: Turner & Reh found "The incidence of sinonasal cancer remained relatively stable during the study period" (1973–2006, PMID:22127982), whereas the 2000–2020 SEER analysis of 488 SNAC patients "indicated a rising incidence" (PMID:39753118).

For prevalence slot annotation: use measure_type: ANNUAL_INCIDENCE, prevalence_class: BELOW_1_IN_1000000, rate_per_100000: 0.044 for sinonasal adenocarcinoma (SEER), with population: United States (SEER, 1973–2013).

Inheritance

Not a heritable disease. No Mendelian inheritance pattern, no penetrance/expressivity/anticipation/mosaicism/founder-effect/consanguinity/carrier-frequency concepts apply. The only germline signal is the unreplicated DDR finding in §2.2. If an Inheritance block is curated at all, it should be SOMATIC/not-applicable rather than any HPO mode-of-inheritance term.

Demographics

• Sex ratio: 94.7% male in the ethmoid/sphenoid ITAC meta-analysis (M:F ≈ 18:1) — occupational, not biological. Male predominance also in SEER SNAC (58.2% male across all sinonasal adenocarcinoma, i.e. much less skewed than ITAC specifically, reflecting non-occupational cases).
• Sporadic cases: ~12%, "typically occur in women with worse prognosis" (PMID:41303732).
• Ethnicity: highest occurrence in White populations in SEER (PMID:39753118) — again likely occupational-cohort composition.
• Geography: ITAC clusters where furniture/leather industries concentrate — northern Italy (Brianza), France, Belgium, the Netherlands, Spain (Asturias), Germany. Countries with predominantly softwood exposure have both lower sinonasal adenocarcinoma incidence and a higher non-ITAC:ITAC ratio (PMID:38711096) — a natural experiment supporting hardwood specificity.

10. Diagnostics

Histopathology — the diagnostic core

Barnes' five morphologic patterns (PMID:3953940): papillary, colonic, solid, mucinous, and mixed. Barnes' own data: "Histologically, five variants of ITAC were recognized: papillary, colonic, solid, mucinous, and mixed."

Kleinsasser & Schroeder's alternative scheme: papillary-tubular cylinder cell (PTCC, graded I–III), alveolar-goblet cell (AGC), signet-ring cell (SRC), transitional (TR). Both schemes are reproducible: interrater agreement 92.6% (κ = 0.89, P < .001) in Franchi's series (PMID:10534159); unanimous agreement in 73% of cases across three independent pathologists in Franquemont's (PMID:2006716).

Both schemes are prognostic, and the mucinous/poorly-differentiated axis is what carries the signal:

"patients with mucinous and poorly differentiated adenocarcinomas had a significantly shorter disease-free interval and survival rate than patients with well and moderately differentiated adenocarcinomas (P = .02 and P < .001) … Therefore, the separation into alveolar-goblet, signet-ring, and transitional forms has no prognostic impact" (PMID:10534159).

Median survivals by Kleinsasser type: PTCC-I 9 years, PTCC-II 3 years, AGC 7 years (PMID:2006716).

Immunohistochemistry

Note "Normal sinonasal epithelia expressed cytokeratin 7, but not CDX-2 and cytokeratin 20" (PMID:15175880) — CDX2/CK20 positivity in sinonasal mucosa is by itself abnormal.

The single most important differential is metastatic colorectal adenocarcinoma, which is immunophenotypically indistinguishable. This must be excluded clinically/radiologically, not by IHC: "it is important for pathologists to remember the association of these tumors with occupational exposure to wood dusts and to exclude metastases of intestinal adenocarcinomas when confronted by these tumors in the sinonasal tract" (PMID:39924774). Other differentials: sinonasal salivary-type adenocarcinoma, low-grade non-ITAC, sinonasal undifferentiated carcinoma, IDH2-mutant sinonasal carcinoma (which can be glandular/poorly-differentiated-adenocarcinoma-like), and olfactory neuroblastoma.

Imaging

CT (bone detail: lamina papyracea, cribriform plate, skull base erosion) plus contrast-enhanced MRI (soft-tissue extent, dural and orbital invasion, distinguishing tumour from obstructed secretions). MRI is essential — the tumour/retained-secretion distinction cannot be made on CT. PET-CT for staging in high-grade/advanced disease.

Biopsy and workup

Endoscopic biopsy is the diagnostic act. Standard workup adds an occupational history — which is diagnostically, prognostically, and medicolegally load-bearing, since ITAC is a compensable occupational disease across the EU.

Molecular testing

• TP53 status / p53 functionality is the one assay with proven treatment-selection value (§12.3). Note it must be sequencing plus functional interpretation, not IHC — see PMID:8685214.
• NGS panel is worthwhile in advanced disease for actionable alterations: "Potentially actionable somatic mutations were found in 20 of 27 cases, 8 of which being biomarkers of FDA-approved targeted therapies" (PMID:33500480). Critically: "thorough interpretation of somatic mutations requires sequencing analysis of the corresponding germline DNA" — paired tumour/normal is not optional in ITAC (57% of variants were germline).
• For non-ITAC low-grade tumours: fusion testing (RNA-based) for ETV6::NTRK3 and other kinase fusions. Directly actionable.
• MMR/MSI: low yield — no MMR alterations found in 32 ITACs (PMID:38791973).
• HER2: low yield — no amplification in 43 ITACs (PMID:31047725).
• Tumour budding should be reported (>4 buds = high) as an independent prognostic variable (PMID:38791973).

Screening

No population screening. Targeted endoscopic surveillance of exposed workers is the rational approach given the long latency and the identifiable precursor (goblet cell hyperplasia → intestinal metaplasia with shared TP53 mutations). The biology supports it — Franchi et al. explicitly frame it as such: "Improving the knowledge on the morphological and molecular features of IM is a key step to identify reliable biomarkers to determine the risk of sinonasal ITAC development" (PMID:25431194). But no validated screening protocol or biomarker exists, and this search found no completed screening trial. Programmes exist in some European occupational-health systems on a national/regional basis.

11. Outcome / Prognosis

Survival (ethmoid/sphenoid ITAC, 1,126 pooled cases; PMID:34622832)

Reported 5-year OS across the wider ITAC literature spans 35–80% depending on stage and histology (PMID:32353928).

Outcomes are improving. "local-recurrence rate was decreasing along the years (r = −0.529, P = .043)" and "5-year overall survival rate was increasing along the years (r = 0.814, P = .011)," attributed to "a shifting trend of treating ethmoid ITACs from an external approach to endoscopic resection" (PMID:34622832). This contrasts with sinonasal cancer overall, where "No significant changes in overall relative survival were noted" over three decades (PMID:22127982) — ITAC is one of the few sinonasal histologies where the outcome curve has actually moved.

Recurrence and mortality pattern

Local recurrence 32.2%, regional 2.2%, distant 10.3% (PMID:34622832). Death is from local/intracranial progression, not systemic disease. Historical Barnes data: 60% dead of disease, 80% of those within 3 years (PMID:3953940).

A cautionary counterpoint from a non-Western series: in 24 patients with follow-up, "Metastases occurred in 19 out of 24 patients. Brain metastases were very common. All patients with metastases died of their disease" (PMID:39924774) — this cohort was 73% high-grade, illustrating how grade distribution drives cohort-level outcomes.

Prognostic factors

Morbidity, disability, quality of life

Function is lost to the treatment as much as to the disease: permanent anosmia after olfactory-cleft resection; orbital exenteration in orbit-invading disease; visual and lacrimal toxicity from radiotherapy to a field abutting the optic nerve and chiasm; chronic crusting, nasal dryness, and CSF-leak risk after extended endoscopic skull-base resection. Knegt's series documents the complication profile of the conservative approach: temporary periorbital swelling 40%, temporary CSF leak 8%, meningitis 1.6%, no perioperative deaths (PMID:11177030). No validated PRO/QoL instrument data for ITAC were identified — a genuine gap.

12. Treatment

12.1 Surgery — the backbone

The primary goal is "complete en bloc resection with negative histological margins (R0)" (PMID:41303732), by endoscopic, open (craniofacial), or combined approach depending on extent, with vascularised-flap skull-base reconstruction.

The field has shifted decisively from craniofacial resection to endoscopic endonasal resection, and this shift is temporally associated with the falling local-recurrence rate and rising 5-year OS documented in PMID:34622832.

NCIT suggestions: NCIT:C15329 Surgical Procedure; NCIT:C157836 Endoscopic Sinus Surgery; NCIT:C180345 Craniofacial Resection; NCIT:C157984 Skull Base Surgery; NCIT:C154430 Definitive Surgical Resection. therapeutic_modality: SURGERY.

12.2 The Rotterdam / Knegt protocol — surgical debulking plus topical 5-FU

A distinctive, ethmoid-specific, organ-preserving alternative to craniofacial resection, with the longest-running outcome data in the disease. Knegt et al., 70 consecutive patients over 23 years (1976–1997), 62 eligible for primary treatment: "Surgical debulking via an extended anterior maxillary antrostomy followed by a combination of repeated topical chemotherapy (fluorouracil) and necrotomy."

"There were no perioperative deaths … Adjusted disease-free survival at 2, 5, and 10 years is 96%, 87%, and 74%, respectively" (PMID:11177030).

These are among the best long-term figures reported for ethmoid adenocarcinoma. Interpret with the usual single-centre-series caveats (selection, era, adjusted-DFS endpoint), but the approach has been independently replicated as "an alternative treatment to craniofacial resection for the management of primary intestinal-type sinonasal adenocarcinoma" (PMC3195981). Typical schedule: topical 5-FU once or twice weekly for 4–6 weeks post-debulking, with interval necrotomy.

Annotation: treatment_term NCIT:C15632 Chemotherapy; therapeutic_agent CHEBI:46345 5-fluorouracil; therapeutic_modality: SMALL_MOLECULE. Worth a notes line that the route is topical/intracavitary, not systemic — the distinguishing feature.

12.3 Induction chemotherapy and the TP53 biomarker — the disease's one precision-oncology story

This is the most striking clinical-molecular result in ITAC, and it is a genuine predictive (not merely prognostic) biomarker.

Licitra et al., J Clin Oncol 2004 (PMID:15611505) — 30 ethmoidal ITAC patients, phase II, cisplatin/5-FU/leucovorin (PFL) then surgery and radiation:

"Twelve patients achieved a pCR; 18 patients did not (overall response rate, 40%). In patients with wild-type (wt) TP53 or functional p53 protein, the pCRs were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P ≤ .0001). At a median 55-month follow-up, all pCR patients were disease-free; 44% of nonresponding patients experienced relapse (P = .0061)."

Note the subtlety in their conclusion: "PFL seems to be highly effective … in the presence of a wt or a still-efficient p53 protein, even when encoded by a mutated TP53 gene (eg, early-stop codon mutation), but ineffective in ITACs carrying a disabled p53 protein." Functional status, not mutation status, is the discriminator — a mutated-but-functional p53 still predicts response.

Bossi et al., Oral Oncol 2013 (PMID:23369851) — 100 consecutive ITAC patients, 74 evaluable for TP53:

"Five-year OS in Group A [craniofacial resection + RT] was 42%, while in Group B [PFL induction + standard treatment] it was 70% (p = 0.041); 5-year DFS in Group A was 40%, while in Group B it was 66% (p = 0.009) … only for Group B patients (who received preoperative chemotherapy) both OS and DFS were in favor of functional p53 (p = 0.023 and p = 0.010). No impact of p53 functional status as a biomarker was observed in Group A."

That last clause is what makes p53 predictive rather than prognostic: it stratifies outcome only in the arm that received the drug.

Annotation: NCIT:C15632 Chemotherapy; agents CHEBI:27899 cisplatin, CHEBI:46345 5-fluorouracil, CHEBI:15640 5-formyltetrahydrofolic acid (leucovorin). No NCIT regimen term for "PLF/PFL" was located — leave regimen_term absent rather than force a mismatched code.

12.4 Radiotherapy

Adjuvant RT is standard for advanced-stage, high-grade, or margin-positive disease. Typical ITAC dose 60 Gy in 30 × 2 Gy fractions, boostable to 66 Gy; non-ITAC is escalated to 66–70 Gy on the basis of perceived radioresistance (PMID:41303732).

Particle therapy is an active area given the proximity of the optic apparatus and brainstem. Carbon-ion RT in 22 patients with locally advanced sinonasal adenocarcinoma gave 3-year local control 76.9% and locoregional control 61.3% (PMID:25287484). Proton therapy for sinonasal cancers broadly: 5-year local control 80%, DFS 62%, cause-specific survival 64%, OS 59% (PMC8270098). The ESMO-EURACAN guideline gives RT advances "a special focus on particle therapy" (PMID:39986703).

NCIT: NCIT:C15313 Radiation Therapy. therapeutic_modality: RADIOTHERAPY.

12.5 Systemic therapy for recurrent/metastatic disease

Largely extrapolated from colorectal regimens given the shared morphology and immunophenotype: 5-FU with oxaliplatin and/or irinotecan has been reported for advanced ITAC (Bull Cancer 2023). Evidence level is case-series.

12.6 Targeted and immunotherapy — status

• HER2-targeted therapy: ruled out. No amplification in 43 tumours (PMID:31047725).
• EGFR-targeted therapy: no rationale. "No EGFR mutations" in 50 ITACs (PMID:34638506).
• Checkpoint inhibitors: limited, subtype-restricted rationale. ITAC is lowly immunogenic; papillary and colonic subtypes with high CD8+ TILs are the plausible candidate group (PMID:32353928).
• PARP inhibition: an untested hypothesis with a real basis. DDR mutations in 32% of tumours, high PARP1 expression in 60%, and HRD mutational signatures on WGS — "The presence of homologous recombination deficiency signatures implies a novel opportunity for treatment, but further studies are needed" (PMID:38711096). No ITAC PARP-inhibitor trial exists.
• NTRK inhibition: relevant to low-grade non-ITAC with ETV6::NTRK3, not to ITAC (PMID:35322195).
• IDH2 inhibition: relevant to IDH2-mutant sinonasal carcinoma, which can present as poorly differentiated sinonasal adenocarcinoma — see NCT06176989 below.

12.7 Active clinical trials (ClinicalTrials.gov, queried 2026-08-28)

No ITAC-specific interventional trial was identified. This is characteristic of the disease — the SINTART 1 and SINTART 2 phase II trials (induction chemotherapy with photon/proton/carbon-ion integration in resectable and unresectable sinonasal tumours) are the main platform studies that enrol these patients, as histology-mixed sinonasal cohorts rather than ITAC trials.

12.8 Pharmacogenomics

No ITAC-specific pharmacogenomic data. Standard DPYD genotyping applies before 5-FU exposure per CPIC/EMA guidance — relevant given how central 5-FU is to both the Knegt protocol and PFL induction, though note the topical route substantially reduces systemic exposure.

12.9 Follow-up

"Clinical examination with endoscopy every 3-4 months (years 1-2)"; contrast-enhanced MRI/CT every 6–12 months for the first 5 years; lifelong follow-up because of "late recurrences … more than five years" post-treatment (PMID:41303732).

NCIT: NCIT:C15747 Supportive Care for symptom management.

13. Prevention

Primary prevention is where nearly all of the achievable benefit lies, because the exposure is known, workplace-confined, and regulable.

• Engineering controls: local exhaust ventilation at source, enclosed cutting/sanding, wet methods, HEPA filtration. Not compressed-air cleaning, which aerosolises settled dust.
• Exposure limits: EU binding OEL for inhalable hardwood dust 2 mg/m³ (down from 3 mg/m³, effective 17 January 2023, under Directive 2017/2398). Germany adopted 2 mg/m³ in March 2021. The threshold is empirically supported: TP53-mutation risk was elevated above 2 mg/m³ average exposure (OR 3.6) (PMID:19950227).
• PPE: appropriately fit-tested respiratory protection as a secondary control.
• Substitution: softwood for hardwood where feasible — supported by the observation that softwood-exposure countries have lower sinonasal adenocarcinoma incidence and relatively more non-ITAC (PMID:38711096).

Secondary prevention: targeted endoscopic surveillance of exposed workers, with biopsy of suspicious mucosa. The precursor-lesion biology (goblet cell hyperplasia → intestinal metaplasia sharing TP53 mutations with the eventual carcinoma) makes this biologically coherent, but no validated protocol, interval, or biomarker exists, and none of the surveillance programmes has been evaluated in a controlled study. A key practical obstacle is the ~40-year latency: surveillance must continue long after the worker has left the industry, which few occupational-health systems handle well.

Tertiary prevention: margin-negative resection, appropriate adjuvant RT, and lifelong endoscopic/imaging surveillance for late local recurrence.

Not applicable: immunisation; genetic screening; carrier screening; PGD/prenatal testing; genetic counselling.

Public health / medicolegal: ITAC is a recognised compensable occupational disease across the EU. Occupational-history documentation at diagnosis is therefore part of standard care, not an optional extra. Sipilä et al. raise an interesting forward-looking application: "Mutational signature analysis may eventually become useful for documentation of occupation-related cancer" (PMID:38711096) — i.e. an ROS-signature-positive ITAC as molecular corroboration of an occupational-exposure claim.

14. Other Species / Natural Disease

• Taxonomy: Homo sapiens, NCBITaxon:9606.
• Naturally occurring homologue: Enzootic nasal adenocarcinoma (ENA) of sheep and goats is the closest natural analogue — a nasal-gland adenocarcinoma caused by enzootic nasal tumour virus (ENTV-1/ENTV-2), a betaretrovirus. It is a genuinely useful comparison because it is mechanistically different: ENA is retrovirally driven, occurs in young animals, and has no dust-exposure component. It illustrates that nasal glandular epithelium can be transformed by more than one route, but it is not a model for wood-dust-associated ITAC.
• Nasal adenocarcinoma occurs sporadically in dogs and cats as part of the canine/feline nasal tumour spectrum; no occupational or wood-dust analogue exists.
• Zoonotic potential: none. ITAC is non-transmissible.
• Comparative pathology and evolutionary conservation: the interesting comparative axis is not cross-species but cross-organ — ITAC versus colorectal adenocarcinoma. They converge on morphology, immunophenotype (CDX2/CK20/MUC2/SATB2), and even karyotype (5q/18q loss, 8q/20q gain), yet diverge on the drivers: "on the level of molecular pathologic mechanisms these tumors have their own specific features different from gastrointestinal tumors" (Leivo, PMID:28321774), with no classical APC-initiated adenoma–carcinoma sequence and markedly lower KRAS mutation rates.
• OMIA: no entry corresponding to this disease.

15. Model Organisms

This is the largest gap in the entire disease. No established preclinical model of sinonasal ITAC was identified in this search — no widely used cell line, no PDX, no organoid, no genetically engineered mouse, and no DepMap entry.

• Genetically engineered models: none reported. The heterogeneous, no-single-driver genetics (§4.1) is precisely what makes a GEMM hard to design — there is no consensus initiating lesion to knock in.
• Chemical/inhalation carcinogenesis models: rodent nasal carcinogenesis models exist for formaldehyde (which produces squamous cell carcinoma, not adenocarcinoma, in rat nasal epithelium) and for other inhaled irritants. No rodent model reproduces wood-dust-induced nasal adenocarcinoma. This is itself a mechanistically informative negative — consistent with the ~40-year human latency and an inflammation/ROS-mediated rather than direct-genotoxic mechanism, neither of which compresses into a rodent lifespan.
• In vitro: work is done on primary/FFPE patient tissue rather than in cultured models; the cited molecular studies are all human tumour-tissue studies (PMID:33500480, PMID:34638506, PMID:38711096).
• Explanted human tissue: the closest thing to a "model" in this field is exposed-worker nasal mucosa biopsy — Palomba's 139 leatherworkers (PMID:18702897) and Franchi's peri-tumoural intestinal metaplasia (PMID:25431194). These are human observational studies, and they are where the precursor-lesion biology actually comes from.

Implication for a KB entry: an animal_models: or experimental_models: section for this disease should be empty with an explicit HUMAN_MODEL_MISMATCH or KNOWLEDGE_GAP discussion attached, rather than populated with a loosely related model. Specifically: evidence for the ROS/inflammation mechanism is entirely correlative human mutational-signature data (PMID:38711096), with no experimental system in which wood dust has been shown to cause sinonasal intestinal metaplasia or adenocarcinoma. That is a KNOWLEDGE_GAP (evidence absent), not a HUMAN_MODEL_MISMATCH (evidence exists but translational validity uncertain).

Consolidated ontology-term suggestions

All CURIEs below were verified against OLS during this research on 2026-08-28.

Disease: MONDO:0002418 ethmoid sinus adenocarcinoma · NCIT:C6237 Ethmoid Sinus Adenocarcinoma · NCIT:C116316 Sinonasal Adenocarcinoma, Intestinal-Type · NCIT:C160977 Sinonasal Adenocarcinoma, Non-Intestinal-Type · pattern-level: NCIT:C160984 papillary, NCIT:C160986 colonic, NCIT:C160987 solid, NCIT:C160995 mucinous

Phenotypes (HP): HP:0001742 Nasal obstruction · HP:0000421 Epistaxis · HP:0031417 Rhinorrhea · HP:0004409 Hyposmia · HP:0000458 Anosmia · HP:0000520 Proptosis · HP:0000651 Diplopia · HP:0009926 Epiphora · HP:0002315 Headache · HP:0030072 Paranasal sinus neoplasm · HP:0000246 Sinusitis · HP:0006824 Cranial nerve paralysis

Anatomy (UBERON): UBERON:0002453 ethmoid sinus · UBERON:0001707 nasal cavity · UBERON:0005385 nasal cavity respiratory epithelium · UBERON:0001825 paranasal sinus · UBERON:0004546 cribriform plate · UBERON:0002363 dura mater · UBERON:0001697 orbit of skull

Cell types (CL): CL:0000066 epithelial cell · CL:0000160 goblet cell · CL:0002370 respiratory tract goblet cell · CL:0000151 secretory cell · CL:0000625 CD8-positive, alpha-beta T cell

Processes (GO): GO:0002544 chronic inflammatory response · GO:0006954 inflammatory response · GO:0006979 response to oxidative stress · GO:0072331 signal transduction by p53 class mediator · GO:0006974 cellular response to DNA damage stimulus · GO:0016055 Wnt signaling pathway · GO:0000165 MAPK cascade · GO:0008283 cell population proliferation

Chemicals (CHEBI): CHEBI:26523 reactive oxygen species · CHEBI:62764 reactive nitrogen species · CHEBI:46345 5-fluorouracil · CHEBI:27899 cisplatin · CHEBI:15640 5-formyltetrahydrofolic acid

Exposures (ECTO): ECTO:7000135 exposure to wood dust · ECTO:7000001 exposure to dust · ECTO:0000439 exposure to formaldehyde · (gap: no exposure to leather dust class exists)

Treatments (NCIT): NCIT:C15329 Surgical Procedure · NCIT:C157836 Endoscopic Sinus Surgery · NCIT:C180345 Craniofacial Resection · NCIT:C157984 Skull Base Surgery · NCIT:C154430 Definitive Surgical Resection · NCIT:C15313 Radiation Therapy · NCIT:C15632 Chemotherapy · NCIT:C15986 Pharmacotherapy · NCIT:C93352 Targeted Therapy · NCIT:C15747 Supportive Care · NCIT:C106432 Pembrolizumab

Ranked evidence base

Summary of gaps for KB curation

1. No MONDO class for sinonasal ITAC — MONDO:0002418 is a subsite proxy. NCIT:C116316 is the semantically correct concept and has no MONDO equivalent.
2. No ECTO term for leather dust exposure — the second-strongest exposure in the disease is unbindable.
3. No preclinical model of any kind. No cell line, PDX, organoid, or GEMM.
4. No transcriptomic, proteomic, metabolomic, single-cell, or spatial data. The disease is genomics-only.
5. No methylation/epigenomic profiling.
6. No QoL / PRO instrument data.
7. No validated surveillance protocol for exposed workers despite a well-characterised precursor lesion.
8. No ITAC-specific interventional trial currently recruiting; patients enrol via histology-mixed sinonasal platform studies.
9. KRAS frequency is genuinely unresolved (0–50% across series) and should be curated as a range with the discordance noted.
10. The pathway-activation/mutation disconnect (p-mTOR 88% vs PI3K mutations 22%; p-ERK 76% vs MAPK mutations 22%) is an open mechanistic question worth a KNOWLEDGE_GAP discussion.

Sources

• Occupational exposure and sinonasal cancer: a systematic review and meta-analysis (PMID:25885319)
• Mutations in TP53 tumor suppressor gene in wood dust-related sinonasal cancer (PMID:19950227)
• Aberrant Signaling Pathways in Sinonasal Intestinal-Type Adenocarcinoma (PMID:34638506)
• Next-generation sequencing for identification of actionable gene mutations in ITAC (PMID:33500480)
• Genome-wide somatic mutation analysis of sinonasal adenocarcinoma with and without wood dust exposure (PMID:38711096)
• Decreasing recurrence and increasing survival rates in ethmoid or sphenoid ITAC: meta-analysis with 1126 cases (PMID:34622832)
• ITAC and Non-ITAC Sinonasal Adenocarcinoma: Classification, Etiopathogenesis, Diagnosis and Therapy (PMID:41303732)
• Epidemiological Features of Sinonasal Adenocarcinoma and Prognostic Nomogram: SEER (PMID:39753118)
• Prediction of TP53 status for primary PFL chemotherapy in ethmoid sinus ITAC (PMID:15611505)
• Tp53 status as guide for the management of ethmoid sinus ITAC (PMID:23369851)
• Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline (PMID:39986703)
• Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil (PMID:11177030)
• Low-grade non-intestinal-type sinonasal adenocarcinoma: molecularly heterogeneous entity (PMID:35322195)
• Intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses — Barnes (PMID:3953940)
• The contemporary management of cancers of the sinonasal tract in adults (PMID:35916666)
• Incidence and survival in patients with sinonasal cancer: SEER historical analysis (PMID:22127982)
• Intestinal-Type Adenocarcinoma: Classification, Immunophenotype, Molecular Features — Leivo (PMID:28321774)
• Genetic and clinical aspects of wood dust related ITAC: a review (PMID:18560862)
• Chromosomal imbalances in wood dust-related adenocarcinomas of the inner nose (PMID:16041693)
• Intestinal metaplasia of the sinonasal mucosa adjacent to ITAC (PMID:25431194)
• CDX-2, CK7 and CK20 in the differential diagnosis of primary sinonasal adenocarcinomas (PMID:15175880)
• A morphologic and immunohistochemical study of nasal mucosa in leatherworkers (PMID:18702897)
• Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal ITAC (PMID:38791973)
• CD8+ TILs and Tumour Microenvironment Immune Types in Sinonasal ITAC (PMID:32353928)
• HER2 status in sinonasal intestinal-type adenocarcinoma (PMID:31047725)
• Intestinal Type Sinonasal Adenocarcinoma: Clinicopathological Study of 48 Patients (PMID:39924774)
• K-ras-2 and p53 genotyping of ITAC of the nasal cavity and paranasal sinuses (PMID:8685214)
• Clinical relevance of the histological classification of sinonasal ITAC (PMID:10534159)
• Histologic classification of sinonasal intestinal-type adenocarcinoma (PMID:2006716)
• Feasibility of carbon ion radiotherapy for locally advanced sinonasal adenocarcinoma (PMID:25287484)
• Long-term Outcomes from Proton Therapy for Sinonasal Cancers
• Endoscopic Resection and Topical 5-FU as an Alternative to Craniofacial Resection for ITAC
• Wood Dust — IARC Summary & Evaluation, Volume 62 (1995)
• Wood Dust — 15th Report on Carcinogens, NCBI Bookshelf
• EU hardwood dust exposure limit value: 3 mg/m³ for 5 years, thereafter 2 mg/m³
• Protecting workers: stricter limits on cancer-causing substances — European Parliament
• Pathology Outlines — Sinonasal adenocarcinoma, intestinal type
• ClinicalTrials.gov NCT06176989 — Enasidenib in IDH2-Mutated Sinonasal and Skull Base Tumors

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:19950227 (abstract only): "Risk of TP53 mutation was significantly increased in association with duration (≥24 years, OR 5.1, 95% CI, 1.5-17.1), average level (>2 mg/m³; OR 3.6, 95% CI, 1.2-10.8) and cumulative level (≥30 mg/m³ × years; OR 3.5, 95% CI, 1.2-10.7) of wood-dust exposure"
• closest text in source: "Risk of TP53 mutation was significantly increased in association with duration (> or =24 years, OR 5.1, 95% CI, 1.5-17.1), average level (>2 mg/m(3); OR 3.6, 95% CI, 1.2-10.8) and cumulative level (> or =30 mg/m(3) x years; OR 3.5, 95% CI, 1.2-10.7) of wood-dust exposure; adjustment for formaldehyde affected the ORs only slightly"
• PMID:8685214 (abstract only): "58% of ITAC demonstrated scattered positive p53 immunohistochemical nuclear staining, but no mutations were identified in exon-5 through exon-8 by genotyping"
• closest text in source: "Fifty-eight percent of ITAC demonstrated scattered positive p53 immunohistochemical nuclear staining, but no mutations were identified in exon-5 through exon-8 by genotyping"
• PMID:31047725 (abstract only): "83.7% (36/43) of ITAC were scored 0, 14% (6/43) 1+, and 2.3% (1/43) 2+. No HER2 amplification was detected by CISH … our findings seem to rule out any oncogenetic role of HER2 in ITAC pathogenesis"
• closest text in source: "Contrary to previous studies, our findings seem to rule out any oncogenetic role of HER2 in ITAC pathogenesis."
• PMID:16041693 (abstract only): "a quantitative as well as a qualitative increase of alterations from PTCC-G1 to PTCC-G2 and finally PTCC-G3 … PTCC-G3 showed significantly more gains of 7q, 8q, and 12p, and losses of 8p and 17p"
• closest text in source: "There was a quantitative as well as a qualitative increase of alterations from PTCC-G1 to PTCC-G2 and finally PTCC-G3, confirming the usefulness of histopathological grading"
• PMID:18702897 (abstract only): "Positivity for MUC-2 was detected in goblet cells of 20 of the 30 samples with goblet cell hyperplasia (66.6%), whereas no immunostaining was observed for cytokeratin 20 and CDX-2. Presence of goblet cell hyperplasia was significantly associated with longer occupational exposure … (p = 0.03)"
• closest text in source: "Positivity for MUC-2 was detected in goblet cells of 20 of the 30 samples with goblet cell hyperplasia (66.6%), whereas no immunostaining was observed for cytokeratin 20 and CDX-2"
• PMID:38791973 (abstract only): "Patients with high TB (>4) have an increased risk of recurrence and death compared to those with low TB, with a median survival of 13 and 54 months, respectively. On multivariate analysis … TB emerged as an independent prognostic factor net of the stage of disease or type of therapy received"
• closest text in source: "Patients with high TB (>4) have an increased risk of recurrence and death compared to those with low TB, with a median survival of 13 and 54 months, respectively"
• PMID:32353928 (abstract only): "The presence of intratumoural CD8+ TILs was low in 57% of cases and high in 8% of cases. Tumoural PD-L1 positivity was observed in 26% of cases … The modest percentage of CD8high/PD-L1pos cases indicates that ITAC is a lowly immunogenic tumour type. Nevertheless, a proportion of ITAC, especially the papillary and colonic subtypes, could benefit from therapy with immune checkpoint inhibitors"
• closest text in source: "Nevertheless, a proportion of ITAC, especially the papillary and colonic subtypes, could benefit from therapy with immune checkpoint inhibitors."
• PMID:41303732 (abstract only): "typically occur in women with worse prognosis"
• Text part not found as substring: 'typically occur in women with worse prognosis' (note: only abstract available for PMID:41303732, full text may contain this excerpt)
• PMID:10534159 (abstract only): "patients with mucinous and poorly differentiated adenocarcinomas had a significantly shorter disease-free interval and survival rate than patients with well and moderately differentiated adenocarcinomas (P = .02 and P < .001) … Therefore, the separation into alveolar-goblet, signet-ring, and transitional forms has no prognostic impact"
• closest text in source: "Kaplan-Meier analysis of cases stratified according to WHO classification showed that patients with mucinous and poorly differentiated adenocarcinomas had a significantly shorter disease-free interval and survival rate than patients with well and moderately differentiated adenocarcinomas (P = .02 and P < .001, respectively; log-rank test)"
• PMID:34622832 (abstract only): "a shifting trend of treating ethmoid ITACs from an external approach to endoscopic resection"
• closest text in source: "There was a shifting trend of treating ethmoid ITACs from external approach to endoscopic resection"
• PMID:41303732 (abstract only): "complete en bloc resection with negative histological margins (R0)"
• closest text in source: "Treatment usually involves surgical resection, often followed by radiotherapy, while the role of chemotherapy remains limited"
• PMID:11177030 (abstract only): "There were no perioperative deaths … Adjusted disease-free survival at 2, 5, and 10 years is 96%, 87%, and 74%, respectively"
• closest text in source: "Adjusted disease-free survival at 2, 5, and 10 years is 96%, 87%, and 74%, respectively"
• PMC:PMC3195981 (abstract only): "an alternative treatment to craniofacial resection for the management of primary intestinal-type sinonasal adenocarcinoma"
• closest text in source: "Intestinal-type adenocarcinoma of the sinonasal tract is very rare and is responsible for less than 4% of tumours of the sinuses"